199 results on '"Koziorowski D"'
Search Results
2. STN DBS improves balance disorders in Parkinson’s disease patients and impacts the disease progression
3. Progressive Supranuclear Palsy Parkinsonism-Predominant (PSP-P) – a problematic entity in the examination of parkinsonisms
4. Brain atrophy correlates with neuropsychological examination in Parkinson’s disease patients
5. Possible impact of subthalamic deep brain stimulation on glycemic variability and lipid profile in patients with Parkinson's disease
6. L-Dopa responsiveness in Perry syndrome (parkinsonism, depression, weight loss, hypoventilation)
7. Amantadine treatment in Parkinson’s disease patients as a modulatory factor of SARS-Cov-2 infection
8. Lipid profile as a differentiating factor in PSP-Richardson-Steele syndrome and Corticobasal syndrome
9. Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
10. Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson's Disease Project.
11. Embracing monogenic Parkinson's disease: the MJFF Global Genetic PD cohort
12. Human nigral and liver iron — comparison by Mössbauer spectroscopy, electron microscopy and ELISA
13. Using global team science to identify genetic parkinson's disease worldwide
14. Paroxysmal dystonia as manifestation of neuromyelitis optica: 1440
15. Reflexive saccadic eye movements latency as biomarker that correlates with UPDRS in Parkinsonʼs disease patients: 895
16. Analysis of gait disorders in Parkinsonʼs disease patients using the three-dimensional motion analysis system: 514
17. Mutations L444P and N370S in the GBA gene in Polish patients with early and later onset Parkinsonʼs disease: 142
18. Higher serum level of NT-proCNP in ropinirole treatment Parkinsonʼs disease: 91
19. On the basis of reflexive saccadic eye (RS) movements responses machine learning (ML) predicts UPDRS in individual Parkinson’s disease (PD) patients: OS1211
20. Cerebral Hypoperfusion in Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS)
21. Human nigral and liver iron – comparison by Mössbauer spectroscopy, electron microscopy and ELISA
22. Using global team science to identify genetic Parkinson's disease worldwide
23. Using global team science to identify genetic parkinson's disease worldwide
24. Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study
25. The neuromodulatory impact of subthalamic nucleus deep brain stimulation on natural history of Parkinson’s disease – a prospective case controlled study
26. Higher serum levels of pro-hepcidin in patients with Parkinson’s disease treated with deep brain stimulation
27. UPDRS III and reflexive saccades latency indicate that STN DBS has therapeutic neuromodulatory effects in Parkinson’s disease
28. STN DBS can temporarily improve balance disorders in Parkinson’s disease patients
29. Evaluation of serum amino acid levels in patients with Parkinson’s Disease
30. The PINK1 p.I368N mutation affects protein stability and disrupts kinase activity
31. Reflex saccades' alterations can estimate long-term motor symptoms' progression in DBS STN and MED Parkinson's disease patients
32. Eye Movement (EM) measurements as objective and precise biomarker for symptoms development in patients with Parkinson's disease
33. The evaluation of kinetic tremor with the use of digitizing tablet as a clinical marker of motor improvement in subthalamic nucleus deep brain stimulation patients with Parkinson’s disease
34. Reflexive saccadic eye movements’ latency correlates with UPDRS in Subthalamic Nucleus Deep Brain Stimulation patients with Parkinson's disease
35. DBS decision support system based on analysis of microelectrode recorded signals as an useful tool in detection of the most beneficial electrode localization during DBS implantation
36. Human nigral and liver iron — comparison by Mössbauer spectroscopy, electron microscopy and ELISA
37. 3.023 FREQUENCY OF THE MUTATIONS IN THE PARK2, PINK1 AND DJ-1 GENES IN POLISH PATIENTS WITH THE EARLY-ONSET PARKINSON DISEASE
38. 3.078 THE NOVEL THAP1 GENE MUTATION, CHARACTERIZED BY PHENOTYPICAL HETEROGENEITY
39. 1.271 MUTATION SPECTRUM OF GENE ENCODING EPSILON-SARCOGLYCAN IN MYOCLONUS-DYSTONIA SYNDROME
40. 1.283 GPI AND STN DBS FOR GENERAL DYSTONIA
41. 1.280 VARIOUS TARGETS FOR DEEP BRAIN STIMULATION FOR VARIOUS TYPES OF DYSTONIA
42. Iron in Alzheimer's and Control Hippocampi - Mössbauer, Atomic Absorption and ELISA Studies
43. P3.098 Molecular analysis PARK2 and DJ-1 mutations in Polish early onset Parkinson's disease patients
44. 2.107 Analysis of the PARK2 mutations in Polish early onset Parkinson's disease patients
45. Ferritin in Parkinsonian and control brains
46. Human nigral and liver iron — comparison by Mössbauer spectroscopy, electron microscopy and ELISA.
47. The neural correlates of specific executive dysfunctions in Parkinson’s disease
48. The neural correlates of specific executive dysfunctions in Parkinson's disease
49. Are botulinum toxin type A preparations really the same medication? a comparison of three botulinum toxin A formulations in labelled neurological indications,Czy wszystkie preparaty toksyny botulinowej typu A sa̧ takie same? Porównanie trzech preparatów toksyny botulinowej typu A w zarejestrowanych wskazaniach w neurologii
50. Changes in serum amino acid levels with progression of Parkinson's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.